Renal, endothelial function, warfarin management, and the CHADS2, CHA2DS2VASc and HAS-BLED scores in predicting MACE in AF

Thrombosis and Haemostasis

Volumn 113, Issue 5, 2015, Pages 1155-1157

  Blann, Andrew D ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; EPIDERMAL GROWTH FACTOR RECEPTOR; VON WILLEBRAND FACTOR; WARFARIN; ANGIOTENSINAMIDE; ANTICOAGULANT AGENT;

AGED; ATRIAL FIBRILLATION; BODY MASS; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR RISK; CHA2DS2 VASC SCORE; CHADS2 SCORE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HAS BLED SCORE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LETTER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SMOKING; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; COMPLICATION; GLOMERULUS FILTRATION RATE; INFLAMMATION; KIDNEY; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AGED; ANGIOTENSIN AMIDE; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; KIDNEY; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT OUTCOME; VON WILLEBRAND FACTOR; WARFARIN;

EID: 84931291699     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-11-0932     Document Type: Letter

References (17)

1. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Am Med Assoc 2001; 285: 2864–2870.
2. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010; 137: 263–272.
3. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest 2010; 138: 1093–1100.
4. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236–239.
5. Piccini JP, Stevens SR, Chang Y, et al.; ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular AF: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in AF) and ATRIA (AnTicoagulation and Risk factors In AF) study cohorts. Circulation 2013; 127: 224–232.
6. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006: 95: 49–55.
7. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37: 2294–2300.
8. Suzuki M, Matsue Y, Nakamura R, et al. Improvement of HAS-BLED bleeding score predictive capability by changing the definition of renal dysfunction in Japanese AF patients on anticoagulation therapy. J Cardiol 2014; Epub ahead of print.
9. Ammash N, Konik EA, McBane RD, et al. Left atrial blood stasis and Von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation. Arterioscler Thromb Vasc Biol 2011; 31: 2760–2766.
10. Freynhofer MK, Gruber SC, Bruno V, et al. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation. Int J Cardiol 2013: 168: 317–325.
11. Roldán V, Marín F, Muiña B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated AF patients. J Am Coll Cardiol 2011; 57: 2496–2504.
12. Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. Thromb Thrombolysis 2013; 35: 333–335.
13. Lee A, Crowther M. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. Thromb Thrombolysis 2011; 31: 249–258.
14. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84–91.
15. Stormorken H, Erikssen J. Plasma antithrombin III and factor VIII antigen in relation to angiographic findings, angina and blood groups in middle-aged men. Thromb Haemost 1977; 38: 874–878.
16. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
17. Hylek EM, Ko D, Cove CL. Gaps in translation from trial to practice: Non-vitamin K antagonist oral anticoagluants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 11: 783–788.